Key statistics
On Wednesday, Arcutis Biotherapeutics Inc (ARQT:NSQ) closed at 26.59, -16.30% below its 52-week high of 31.77, set on Dec 08, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 26.91 |
|---|---|
| High | 27.18 |
| Low | 25.84 |
| Bid | 25.97 |
| Offer | 26.97 |
| Previous close | 26.88 |
| Average volume | 1.21m |
|---|---|
| Shares outstanding | 122.49m |
| Free float | 120.45m |
| P/E (TTM) | -- |
| Market cap | 3.29bn USD |
| EPS (TTM) | -0.3545 USD |
Data delayed at least 15 minutes, as of Feb 11 2026 21:00 GMT.
More ▼
Announcements
- Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis
- Arcutis Biotherapeutics, Inc. Announces Termination of Promotion Agreement with Kowa
- Nationwide Survey Underscores Concerns with Use of Topical Steroids and Need for Long-Term Treatment Strategies Facing the 46 Million Americans with Chronic Inflammatory Skin Conditions
- Arcutis Highlights 2026 Strategic Priorities and Anticipated Milestones
- Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri
- FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5
- Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis
- Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology
- Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term Treatments
- Arcutis Launches ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5
More ▼
